

Beamtree[®]

FY26

FY26 Annual Results

28th August 2026

Authorised for release by a duly authorised sub-committee of the Board





Beamtree[®]

The background of the image is a solid purple color. Overlaid on this background is a faint, light-colored network diagram. The diagram consists of numerous circular nodes of varying sizes, connected by thin, light-colored lines. Some nodes are larger and more prominent, while others are smaller. The connections form a complex, web-like structure that spans the right side of the image. In the upper right corner, there are faint, stylized representations of binary code (0s and 1s) arranged in a grid-like pattern.

Highlights

Strategic Review completed

Focus on high value products

Business process improvements

Product investment to drive growth

Financial Performance

Recurring Revenue up 10.1% to \$27.5m

Positive Operating Profit of \$362k

Tight cost control

Balance Sheet

Restructured Debt Facility

Write-down of Intangible Assets

Helping healthcare providers deliver better care

Our segments



Coding



Software to audit the quality and accuracy of clinically coded information, enabling hospitals to maximise complexity recognition and assure revenue received from payers while supporting the efficient use of clinical coding resources through automation.



Analytics



Platforms that collate clinical data analysis with peer benchmarking across entire countries, to drive better care and efficient use of scarce resources across health services with informed decisions.



Diagnostic



AI tools to enable users to build expert rules for repeatable clinical and non-clinical tasks, creating time and cost savings in diagnostics services, while providing safer, consistent care to patients.

Leading healthcare tech company focused on innovative AI enhanced solutions for coded data in the hospital and pathology markets



Coding
(30% of revenue)

73%

Of acute patient records in Australia
processed by Beamtree



Analytics
(42% of revenue)

>10k

Unique benchmarks across ANZ in
Health Roundtable



Diagnostics
(28% of revenue)

100m+

Cases interpreted through
RippleDown each year

Leading healthcare tech company focused on innovative AI enhanced solutions for coded data in the hospital and pathology markets

Coding



15 years of experience in Hospital clinical data coding assurance in Australia, New Zealand. Operating in Ireland, Saudi and Canada



Coding Services supporting clients for over 15 years now over 200 clients in 4 continents

Analytics



Experts in Hospital and health systems analytics and benchmarking for more than 30 years. Supporting whole of system member services in ANZ and now the UK




Health Roundtable servicing ANZ for over 30 years

Diagnostics



Automation of clinical decision support in Laboratory services in over 25 countries for over 25 years



Beamtree and RippleDown have been serving labs for more than 25 years in over 25 countries

Deep product capability

Deep customer relationships

- Built for our Partner
- Long term customers
- High bar for accuracy

Extensive domain expertise

- Operational and clinical hospital data going back decades
- Standards and degrees of complexity which differ by geography

'Trusted' Ai


- AI deployed with in Strong guard rails
- Leverage of decades of experience
- Existing and new products

Highly regulated environment

- IHACPA, AIHW, HIMAA (Aus)
- SHC, MOH, CNHI, CHI, SCFHS, SHIMA (Saudi)
- CIHI, Health Canada, Provincial MoHs, CHIMA (Can)
- NHS England, NICE, ICBs, IHRIM (England)



Focused Markets



FY26 Financial Results

Beamtree[®]

Profit and Loss

	FY25	FY26	FY26 Growth
Total Recurring Revenue	25.0	27.6	10%
Analytics	11.1	12.2	9%
Diagnostics	7.5	7.9	6%
Coding	5.9	7.2	21%
Clinical decision support	0.5	0.3	(32%)
Non-Recurring Revenue	3.6	1.6	(54%)
Total Revenue	28.6	29.2	2%
Expenses – people	(20.6)	(21.5)	5%
Expenses – non people	(7.3)	(7.3)	0%
Total Operating Expenses	(27.9)	(28.8)	3%
Operating Profit	0.7	0.4	(50%)
Non-operational income & expense	(1.4)	(0.1)	(96%)
Goodwill impairment	-	(9.6)	100%
Software impairment	-	(3.6)	100%
Depreciation & amortisation	(5.5)	(5.1)	(7%)
Interest expense	(0.2)	(0.2)	41%
Income tax benefit/(expense)	0.2	(0.1)	(145%)
Net Profit/(Loss) after Income Tax	(6.2)	(18.3)	(197%)



Recurring revenue up 10%

High-quality recurring revenue makes up 95% of total revenue.

Low churn.

Clinical Decision support discontinued



Expense control - \$29.2m

Continued focus on cost management



Goodwill Impairment - \$9.6m

Forecast impacted by discontinued products & reassessed growth rates for international markets. Non-cash.



Software impairment - \$3.5m

Reviewed useful life of acquired software now fully integrated, which is now rewritten into the base product. Re-platformed software written off





Underlying ARR - \$25.4m

Excludes discontinued products \$1.7m

*adjusted for roundings

CONFIDENTIAL

Recurring Revenue by Product and Geography



Balance Sheet

	FY25	FY26
Current Assets		
Cash and cash equivalents	4.8	2.5
Trade and other receivables	4.7	5.2
Contract assets	0.1	0.3
Total Current Assets	9.6	8.0
Non-Current Assets		
Property, plant and equipment	0.2	0.2
Right-of-use assets	0.9	0.7
Intangible assets	41.8	27.8
Deferred tax assets	1.7	0.8
Total Non-Current Assets	44.7	29.4
Current Liabilities		
Trade and other payables	3.4	3.2
Borrowings	-	3.3
Contract liabilities	2.8	4.6
Other current liabilities	1.7	1.7
Total Current Liabilities	7.8	12.8
Non-Current Liabilities		
Lease liabilities	0.7	0.5
Borrowings	2.3	-
Other non-current liabilities	1.5	0.7
Total Non-Current Liabilities	4.5	1.2
Net Assets	41.9	23.4



Intangibles assets \$27.8m - \$13.3m

Goodwill impairment – \$9.6m
Software impairment - \$3.6m



Borrowings

Current as at June 26 – waiver received Aug 26
Non-current at half year
Restructured covenant to align with business needs



Liquidity – \$5.5m

Cashflow

	FY25	FY26	Variance
Operating Activities			
Receipts from customers (inclusive of GST)	31.7	33.2	
Payments to suppliers and employees (inclusive of GST)	(31.1)	(32.2)	
Interest received	0.0	0.1	
Interest and other finance costs paid	(0.1)	(0.2)	
Net Cash from Operating Activities	0.6	0.9	0.4
Investing Activities			
Payments for property, plant and equipment	(0.2)	(0.1)	
Payments for intangibles	(2.3)	(3.7)	
Net Cash from Investing Activities	(2.5)	(3.8)	(1.3)
Financing Activities			
Repayment of lease liabilities	(0.3)	(0.3)	
Proceeds from debt facility	2.3	1.0	
Other financing activities	(0.4)	-	
Net Cash from Financing Activities	1.6	0.7	0.9
Net Increase/(Decrease) in Cash & Cash Equivalents	(0.3)	(2.3)	
Opening Cash & Cash Equivalents	5.0	4.8	
Closing Cash & Cash Equivalents	4.8	2.5	(2.3)

* Includes \$1.85m of cash from initial draw down of debt facility.
Copyright © Beamtree Holdings Limited – All Rights Reserved



Positive operating Cash flow

Focus on working capital management



Continue to invest in our unique IP

FY26 investment in Evolve
Targeted product expansion



Cash on hand \$2.5m

Remaining \$3.0m undrawn facility

FY27 Priorities

Beamtree[®]

FY27 Priorities



Priorities

- 1 Execution & Focus
- 2 Leverage our IP to bring value to our partners
- 3 Continued focus on ARR growth through established & new products



Beamtree[®]

The partner between patient and healthcare provider

Thank you

Beamtree®

Beamtree - an Australian company with global reach.



A leading healthcare technology company focused on innovative AI enhanced solutions for data quality assurance in the hospital, benchmarking to promote best practice, and automation in diagnostics care.

Hospital clinical **coding** tools,
PICQ, RISQ and PICQ Audit

(30% of revenue)

- Audited ~8 mill patient episodes from 362 sites last financial year (>70% of all admissions ANZ) now operating in Ireland, Canada and Saudi.
- PICQ audit providing approx. \$4 mill uplift pa per client

“

"Beyond the immediate identification of coding opportunities, the PICQ® Audit program helped strengthen visibility of clinical complexity across our Local Health District. By applying a structured, data-driven audit methodology, the district was able to systematically review episodes where diagnoses may influence funding outcomes."

Health systems **analytics** and benchmarking,
Health Roundtable

(42% of revenue)

- 189 member hospitals across ANZ, 176,000 dashboard interactions pa, covering 80% of acute activity across the region.

“

"I've seen the value in having robust, timely, comprehensive and, I use the word intelligence, not data deliberately, intelligence to improve care, particularly where it's able to be peer assessed for sustained improvement."

Automated decision support in labs,
RippleDown Auditor and Expert

(28% of revenue)

- Processing over 100mill episodes pa for direct customers
- Generating over \$8million in savings for every million episodes.
- Automating 90% of reporting in client labs

“

"The implementation of RippleDown in our Haematology department has had an enormous positive impact on our workload and the quality of the reports that we provide. The ongoing support of Beamtree with this work is absolutely phenomenal."

Important Notice and Disclaimer

The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, August 2026.

This presentation may contain statements that are, or may be deemed to be, forward looking statements. Such statements can generally be identified by the use of words such as “believe”, “estimate”, “plan”, “target”, “project”, “anticipate”, “expect”, “intend”, “likely”, “may”, “will”, “could” or “should” and similar expressions. Indications of strategy, plans, objectives, targets, goals, future events or intentions are also forward-looking statements.

You should not place undue reliance on such forward-looking statements. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of BMT or any of its related entities which may cause actual results to differ materially from those expressed or implied in such statements.

No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation. Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

The information in the presentation is given for informational purposes only, is in summary form and does not purport to be complete. It is intended to be read by a professional analyst audience in conjunction with BMT’s other announcements to ASX. It is not intended to be relied upon as advice to current shareholders, investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor. No representation is made as to the accuracy, completeness or reliability of the presentation.

The views expressed in this presentation may contain information that has been derived from publicly available sources that have not been independently verified. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information. Market share information is based on management estimates except where explicitly identified.

To the maximum extent permitted by law, BMT and any person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation, any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

BMT is not obliged to, and does not represent that it will, update the presentation for future developments. All currency figures are in Australian dollars unless otherwise stated. Totals may not add up precisely due to rounding.